Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 30 – June 3 in Chicago.
GALAXY-2 trial design
“GALAXY-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma”
Help employers find you! Check out all the jobs and post your resume.
